Bishii Luulyo 5, Novo Nordisk waxay bilawday wajiga III tijaabada bukaan-socodka CagriSema ee Shiinaha, ujeedada taas oo ah in la barbardhigo badbaadada iyo waxtarka duridda CagriSema oo leh semeglutide ee bukaannada cayilan iyo kuwa cayilan ee Shiinaha.
Cirbadeynta CagriSema waa daaweyn isku-dhafan oo muddo dheer socota oo ay horumarinayso Novo Nordisk, qaybaha ugu muhiimsan waa GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide iyo amylin analog cagrilintide muddo dheer shaqaynaysa.Cirbadeynta CagriSema waxaa la isku duri karaa maqaarka hoostiisa hal mar todobaadkii.
Ujeeddada aasaasiga ah waxay ahayd in la is barbar dhigo CagriSema (2.4 mg/2.4 mg) oo leh semeglutide ama placebo hal mar toddobaad kasta oo hoostiisa ah.Novo Nordisk ayaa ku dhawaaqday natiijada tijaabada CagriSema ee loogu talagalay daawaynta heerka 2aad ee sonkorowga, taas oo cadaysay in saamaynta hypoglycemic ee CagriSema ay ka fiican tahay kan semeglutide, iyo ku dhawaad 90% maadooyinka ayaa gaadhay yoolka HbA1c.
Xogta ayaa muujisay in marka lagu daro saameynta hypoglycemic ee muhiimka ah, marka la eego miisaanka dhimista, CagriSema cirbadeynta ayaa si weyn uga sarreysa semeglutide (5.1%) iyo cagrilintide (8.1%) oo leh miisaan lumis ah 15.6%.
Daawada hal-abuurka leh ee Tirzepatide waa agonist-ta soo dhawaynta GIP/GLP-1 ee toddobaadlaha ah ee ugu horreysa ee la oggolaaday.Waxay isku daraysaa saamaynta laba incretins ee hal unug oo la isku duro todobaadkiiba hal mar waana nooc cusub oo daawaynta nooca 2aad ee sonkorowga.Tirzepatide waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) bishii Maajo 2022 si loo hagaajiyo xakamaynta glycemic (ku salaysan cunto iyo jimicsi) dadka qaangaarka ah ee qaba nooca 2 ee sonkorowga waxaana hadda laga ansixiyay Midowga Yurub, Japan iyo dalal kale.
Bishii Luulyo 5, Eli Lilly wuxuu ku dhawaaqay wejiga III SURPASS-CN-MONO daraasad ku saabsan diiwaangelinta tijaabada bukaan-socodka daawada iyo madal siidaynta macluumaadka loogu talagalay daaweynta nooca 2 ee bukaannada sonkorowga.SURPASS-CN-MONO waa daraasad la kala soocay, laba-indho la'aan, daraasad lagu xakameynayo booska III ee loogu talagalay in lagu qiimeeyo waxtarka iyo badbaadada monotherapy tirzepatide marka la barbar dhigo placebo ee dadka qaba nooca 2 ee sonkorowga.Daraasada ayaa la qorsheeyay in lagu daro 200 bukaan oo qaba nooca 2 ee sonkorowga kuwaas oo aan qaadan wax dawooyinka ka hortagga sonkorowga 90 maalmood ka hor booqashada 1 (marka laga reebo xaaladaha caafimaad qaarkood, sida jirro degdeg ah, isbitaal dhigga, ama qalliin la doortay, waqti gaaban (≤14) maalmo) isticmaalka insulin).
Nooca 2-aad ee xanuunka macaanka ayaa la filayaa in la ogolaado sanadkan
Bishii la soo dhaafay, natiijadii daraasad SURPASS-AP-Combo ah ayaa lagu daabacay Maajo 25 ee joornaalka blockbuster ee Nature Medicine.Natiijooyinku waxay muujiyeen in marka la barbardhigo glargine insulin, Tirzepatide waxay muujisay HbA1c ka wanaagsan iyo hoos u dhigista miisaanka dadweynaha nooca 2 ee bukaannada cudurka macaanka ee gobolka Aasiya-Pacific (badanaa Shiinaha): Hoos u dhigista HbA1c ilaa 2.49% iyo dhimista miisaanka ilaa 7.2 kg. (9.4%) 40 toddobaad oo daawaynta ah, horumar la taaban karo oo ku yimid dufannada dhiigga iyo cadaadiska dhiigga, iyo guud ahaan badbaadada iyo dulqaadku waxay ahaayeen kuwo wanaagsan.
Tijaabada bukaan-socodka ee Wajiga 3 ee SURPASS-AP-Combo waa Tirzepatide daraasaddii ugu horreysay ee lagu sameeyo bukaannada Shiinaha ee qaba nooca 2-aad ee sonkorowga, oo uu hoggaamiyo Professor Ji Linong oo ka tirsan Isbitaalka Dadka ee Jaamacadda Peking.SURPASS-AP-Combo waxay la socotaa natiijooyinka taxanaha SURPASS ee caalamiga ah ee cilmi-baarista, taas oo sii caddaynaysa in pathophysiology ee cudurka macaanka ee bukaannada Shiinaha ay la socdaan kuwa bukaanka caalamiga ah, taas oo saldhig u ah cilmi-baarista isku mar ah iyo horumarinta daawooyinka cusub. Shiinaha iyo adduunka oo dhan, iyo sidoo kale waxay bixisaa taageero caddayn ah oo lagu siinayo bukaannada Shiinaha fursad ay ku isticmaalaan daawooyinkii ugu dambeeyay ee daaweynta sonkorowga iyo codsigooda caafimaad ee Shiinaha sida ugu dhakhsaha badan.
Waqtiga boostada: Seb-18-2023